Pharmaceutical Intermediates Deferasirox for Hemochromatosis CAS 201530-41-8

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Solid
• Purity: >99%
• Model NO.: TGY022019042602
• Product Name: Deferasirox
• Appearance: White Powder
• Specificcation: 99%
• CAS No.: 201530-41-8
• Grade: Pharmaceuticals Grade
• Shelf Life: 2 Years
• Storage: Cool Dry Place
• Shipping Time: Within 3-7 Working Days
• Transport Package: Foil Bag, Box, Drum
• Specification: 99% min
• Trademark: TGY
• Origin: China
• HS Code: 293729002
• Production Capacity: 1000kg/Month

Product Description

<sub>Product Name: Deferasirox 
Synonyms: 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid;deferasirox;Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-;Deferasirox for research;4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic Acid;CGP-72670;Exjade;ICL-670 
CAS: 201530-41-8 
MF: C21H15N3O4
MW: 373.3615
Product Categories: Chelating agent (iron);Aromatics Compounds;Aromatics;Chelating Agents & Ligands;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate;Exjade, ICL-670, ICL-670A, CGP-72670
Melting point  260-262ºC 
Storage temp.  -20°C Freezer
Chemical Properties White to Off-White Solid 
Usage Orally active tridentate iron chelator 
Usage Biological Activity Chemical Information Tech Support & FAQs Biological Activity Deferasirox(Exjade) is a rationally-designed oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions 
Usage A tridentate chelator that binds iron with high affinity .
Usage Labeled Deferasirox, intended for use as an internal standard for the quantification of Deferasirox by GC- or LC-mass spectrometry. 

Deferasirox: chemical name 4- [3,5-bis (2-hydroxyphenyl) -1,2,4-triazol-1-yl] benzoic acid, is a kind of iron chelator products studied and developed by the Novartis company (Swiss). It was the first routinely used oral iron agent approved by US FDA, allowed to be applied for the treatment of iron overloading caused by blood transfusion in patients (older than 2 years old) of chronic anemia. In Europe, it is recommended as the first-line treatment drug for patients older than 6-year-old who are suffering blood iron overload patients.
In China, it is currently subject to clinical research; 2, 3 clinical trials and pharmacokinetic studies have all shown that it has excellent safety and tolerability, and can significantly reduce the heart, liver iron load, easy to be accepted by the patient. At the same time, it also has pharmacological properties of antifungal (such as Mucor which can grow in iron-ricking environment), anti-cell proliferation, anti-malaria, antioxidant stress injury and anti-cytotoxicity induced apoptosis; it can be used for the treatment of hemochromatosis, delayed skin porphyria and other diseases.</sub> 

<sub>1. DFS can be used to treat the reversible renal insufficiency caused by Fanconi syndrome.
2. It can be used for the treatment of secondary hemochromatosis.
3. It can be used for the treatment of delayed skin porphyria.
4. It can be used for the treatment of myelodysplastic syndromes.
5. It can be used for the treatment of iron overloading caused by blood transfusion for patients (older than 2 years old) of chronic anemia .</sub>

                                              Product Photo                                                       


 

                                          Customers Reviews